Abiopharma

ImmunoGen Inc (was acquired by AbbVie (NYSE: ABBV) on 12/02/2024) (IMGN) Announces Clinical Trial Update ImmunoGen Inc (was acquired by AbbVie (NYSE: ABBV) on 12/02/2024) (IMGN) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: improvements
• Collaboration: BLA
  • anticipated interactions with regulatory authorities; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen’s industry and business; and other factors as set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022
  • targeting agent, to kill the targeted cancer cells. ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™. Learn more about who we are, what we do, and how we do it at www.immunogen.com. FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. These statements include, but are not limited to, ImmunoGen’s expectations related to: the occurrence, timing, and outcome of potential clinical and regulatory events related to the Company’s product candidates, including the review of the Company’s BLA to the FDA for mirvetuximab and full approval of mirvetuximab; the commercial launch of mirvetuximab and the potential of mirvetuximab to serve as a new standard of care for patients with platinum-resistant ovarian cancer; and the presentation of preclinical and clinical data on the Company’s product candidates, including top-line data from the MIRASOL trial in early 2023